Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study

Kristel M. Crommentuyn; Alwin D. Huitema; Kees Brinkman; Marchina van der Ende; Frank de Wolf; Jos H. Beijnen

doi:10.1097/01.qai.0000163026.47147.67

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study

Kristel M. Crommentuyn
, Alwin D. Huitema
, Kees Brinkman
, Marchina van der Ende
, Frank de Wolf
, Jos H. Beijnen

Internal Medicine

Slotervaart Hospital
Onze Lieve Vrouwe Gasthuis
HIV Monitoring Foundation
Utrecht University

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

16 Citations (Scopus)

6 Downloads (Pure)

Abstract

To the Editor:

Therapeutic drug monitoring (TDM) implies individualized dosing of a drug by analysis and interpretation of the plasma drug concentrations. We investigated whether routine TDM of nevirapine in treatment-naive HIV-1-infected patients has an effect on its pharmacokinetics, and thus on the occurrence of toxicity and the virologic response to treatment. Our analysis was performed within the framework of the ATHENA study, a national observational cohort of HIV-infected patients followed in 22 treatment centers in The Netherlands [...]

Original language	English
Pages (from-to)	249-250
Number of pages	2
Journal	Journal of Acquired Immune Deficiency Syndromes (1999)
Volume	39
Issue number	2
DOIs	https://doi.org/10.1097/01.qai.0000163026.47147.67
Publication status	Published - Jun 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-04-28-04

Access to Document

10.1097/01.qai.0000163026.47147.67

therapeutic_drug_monitoring_of_nevirapine_reduces.18Final published version, 105 KB

Cite this

Crommentuyn, K. M., Huitema, A. D., Brinkman, K., van der Ende, M., de Wolf, F., & Beijnen, J. H. (2005). Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study. Journal of Acquired Immune Deficiency Syndromes (1999), 39(2), 249-250. https://doi.org/10.1097/01.qai.0000163026.47147.67

@article{6f95485063d5487a83565da558076108,

title = "Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study",

abstract = "To the Editor: Therapeutic drug monitoring (TDM) implies individualized dosing of a drug by analysis and interpretation of the plasma drug concentrations. We investigated whether routine TDM of nevirapine in treatment-naive HIV-1-infected patients has an effect on its pharmacokinetics, and thus on the occurrence of toxicity and the virologic response to treatment. Our analysis was performed within the framework of the ATHENA study, a national observational cohort of HIV-infected patients followed in 22 treatment centers in The Netherlands [...]",

author = "Crommentuyn, \{Kristel M.\} and Huitema, \{Alwin D.\} and Kees Brinkman and \{van der Ende\}, Marchina and \{de Wolf\}, Frank and Beijnen, \{Jos H.\}",

year = "2005",

month = jun,

doi = "10.1097/01.qai.0000163026.47147.67",

language = "English",

volume = "39",

pages = "249--250",

number = "2",

}

Crommentuyn, KM, Huitema, AD, Brinkman, K, van der Ende, M, de Wolf, F & Beijnen, JH 2005, 'Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study', Journal of Acquired Immune Deficiency Syndromes (1999), vol. 39, no. 2, pp. 249-250. https://doi.org/10.1097/01.qai.0000163026.47147.67

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study. / Crommentuyn, Kristel M.; Huitema, Alwin D.; Brinkman, Kees et al.
In: Journal of Acquired Immune Deficiency Syndromes (1999), Vol. 39, No. 2, 06.2005, p. 249-250.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study

AU - Crommentuyn, Kristel M.

AU - Huitema, Alwin D.

AU - Brinkman, Kees

AU - van der Ende, Marchina

AU - de Wolf, Frank

AU - Beijnen, Jos H.

PY - 2005/6

Y1 - 2005/6

N2 - To the Editor: Therapeutic drug monitoring (TDM) implies individualized dosing of a drug by analysis and interpretation of the plasma drug concentrations. We investigated whether routine TDM of nevirapine in treatment-naive HIV-1-infected patients has an effect on its pharmacokinetics, and thus on the occurrence of toxicity and the virologic response to treatment. Our analysis was performed within the framework of the ATHENA study, a national observational cohort of HIV-infected patients followed in 22 treatment centers in The Netherlands [...]

AB - To the Editor: Therapeutic drug monitoring (TDM) implies individualized dosing of a drug by analysis and interpretation of the plasma drug concentrations. We investigated whether routine TDM of nevirapine in treatment-naive HIV-1-infected patients has an effect on its pharmacokinetics, and thus on the occurrence of toxicity and the virologic response to treatment. Our analysis was performed within the framework of the ATHENA study, a national observational cohort of HIV-infected patients followed in 22 treatment centers in The Netherlands [...]

UR - https://www.researchgate.net/publication/7835338_Therapeutic_drug_monitoring_of_nevirapine_reduces_pharmacokinetic_variability_but_does_not_affect_toxicity_or_virologic_success_in_ATHENA_study

U2 - 10.1097/01.qai.0000163026.47147.67

DO - 10.1097/01.qai.0000163026.47147.67

M3 - Comment/Letter to the editor

C2 - 15905743

SN - 1525-4135

VL - 39

SP - 249

EP - 250

JO - Journal of Acquired Immune Deficiency Syndromes (1999)

JF - Journal of Acquired Immune Deficiency Syndromes (1999)

IS - 2

ER -

Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study

Abstract

UN SDGs

Research programs

Access to Document

Other files and links

Fingerprint

Cite this